The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278 · cited 3×
“Indeed, preclinical studies using rodent have indicated that depressive-like behaviors induced by immune activation using LPS and bacillus CalmetteeGu erin (BCG) are mediated by IDO1 activation (O'Connor et al., 2009a; O'Connor et al., 2009b).”
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 2×
“First of all, QUIN is a neurotoxic KP metabolite that activates NMDA receptors, increases neuronal activity, and elevates intracellular calcium concentrations (Stone and Perkins, 1981).”
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“…several studies have demonstrated that IFNa therapy, used to treat hepatitis C and malignant melanoma, promotes depression symptoms in treated patients and that the severity of symptoms is correlated with the degree of elevation of QUIN level in the CSF (Baranyi et al., 2015; Raison et al., 2010).”
Self-citationQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Interferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 2×
“Microglial activation appears to correlate with HD severity (Pavese et al., 2006), and reactive microglia accumulate in the brain regions associated with the greatest HDassociated neurodegeneration (Sapp et al., 2001).”
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445 · cited 3×
“…Savitz et al., 2015a, 2015c, 2015d) (Depression with HCV receiving IFNa therapy) [ KYN/TRP (up-regulation of IDO) Serum (human) (Comai et al., 2011; Wichers et al., 2005) [ KYN/KYNA (up-regulation of IDO and/or downregulation of KAT branch) Serum (human) (Wichers et al., 2005) (Depression with…”
InfluentialBonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
Indoleamine 2,3-dioxygenase. Purification and some properties
Shimizu, T., Nomiyama, S., Hirata, F., & Hayaishi, O. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30447-7 · Cited by 367 · cited 2×
“…is the oxidative cleavage of TRP by one of the three rate-limiting enzymes, namely, tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), or indoleamine 2,3- dioxygenase 2 (IDO2), which convert TRP to N-formylkynurenine (Ball et al., 2007; Metz et al., 2007; Shimizu et al., 1978).”
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Differential vulnerability of central neurons of the rat to quinolinic acid
Schwarcz, R., & Köhler, C. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90115-5 · Cited by 239
Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients
Huengsberg, M., Winer, J. B., Gompels, M., Round, R., Ross, J., & Shahmanesh, M. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.4.858 · Cited by 172
Cited by
Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health
Parker, A., Fonseca, S., & Carding, S. R. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1638722 · Cited by 702
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
“However, the abnormal build-up of kynurenic acid can induce glutamatergic hypofunction, possibly disturbing cognitive functioning [205].”
BackgroundGut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Metadata
- Authors
- Fujigaki, H., Yamamoto, Y., & Saito, K.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 112
- Issue
- Pt B
- Pages
- 264-274
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2223880435
- Cited by
- 178
- References
- 19
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.